Machine signal
Active cluster sell — 4 distinct insiders, $34.6M, window ends Nov 16, 2026.
Figures computed from official regulatory filings — .
Analysttarget 131.5 USD (+15%) · consensus 3.82/5 · 13 buy · 14 hold · 1 sell
Ownershipinsiders 2.18% · institutions 101.64% · short 8.9% of float · 5.54d to cover
In USD · as of Nov 16, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for INCYTE CORP only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Market information source · Nov 16, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Nov 16, 2026
Purchases and sales · full history
537 buys704 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| CAGNONI PABLO J | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| CAGNONI PABLO J | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| CAGNONI PABLO J | Exercise | $60.3K | SEC | ||
| Stein Steven H | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| CAGNONI PABLO J | Exercise | $26.1K | SEC | ||
| Stein Steven H | Exercise | $39.3K | SEC | ||
| CAGNONI PABLO J | Sell | $212.6K | SEC | ||
| CAGNONI PABLO J | Sell | $107K | SEC | ||
| CAGNONI PABLO J | Exercise | $59.5K | SEC | ||
| CAGNONI PABLO J | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| CAGNONI PABLO J | Exercise | $27.8K | SEC | ||
| CAGNONI PABLO J | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Stein Steven H | Sell | $70.3K | SEC | ||
| Heeson Lee | Sell | $265K | SEC | ||
| Heeson Lee | Sell | $445.2K | SEC | ||
| Heeson Lee | Sell | $296.7K | SEC | ||
| Heeson Lee | Sell | $105.9K | SEC | ||
| Heeson Lee | Sell | $179.3K | SEC | ||
| Stein Steven H | Exercise | $1.1M | Unusual size | SEC | |
| Stein Steven H | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Stein Steven H | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Stein Steven H | Sell | $8.8M | Unusual size | SEC | |
| Stein Steven H | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Stein Steven H | Exercise | $1.4M | Unusual size | SEC | |
| Stein Steven H | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |